Literature DB >> 16819667

[Potential antinociceptive mechanisms of botulinum toxin].

K R Aoki1, J Francis, W H Jost.   

Abstract

Botulinum toxin has been used in pain therapy for several years. Its application in migraine and headaches is particularly interesting. Clinical results have not yet been definitely conclusive, and a uniform model of the mode of action has not been established either. Apart from a purely muscular effect, a direct antinociceptive effect of botulinum toxin has been found in patients, in the preclinical model, and in a clinical pain model. This is contradicted by negative observations in the clinical model of pain, which might be related to methodological deficits. Further basics need to be worked out before arriving at any final result. Clinical studies with patients and pain models should then follow. Studying botulinum toxin within the context of pain will also provide many new insights into pain therapy in general. In which pain model botulinum toxin may play a role in the future, has to be awaited.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819667     DOI: 10.1007/s00482-006-0487-2

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  36 in total

1.  A new method to increase nociception specificity of the human blink reflex.

Authors:  H Kaube; Z Katsarava; T Käufer; H Diener; J Ellrich
Journal:  Clin Neurophysiol       Date:  2000-03       Impact factor: 3.708

2.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors:  M J Welch; J R Purkiss; K A Foster
Journal:  Toxicon       Date:  2000-02       Impact factor: 3.033

3.  A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects.

Authors:  Thomas Sycha; Burkhard Gustorff; Stephan Lehr; Adrian Tanew; Hans-Georg Eichler; Leopold Schmetterer
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

4.  A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model.

Authors:  Thomas Sycha; Doris Samal; Boris Chizh; Stephan Lehr; Burkhard Gustorff; Peter Schnider; Eduard Auff
Journal:  Anesth Analg       Date:  2006-02       Impact factor: 5.108

5.  Botulinum toxin types A, B and D inhibit catecholamine secretion from bovine adrenal medullary cells.

Authors:  D E Knight
Journal:  FEBS Lett       Date:  1986-10-27       Impact factor: 4.124

Review 6.  Neuronal plasticity: increasing the gain in pain.

Authors:  C J Woolf; M W Salter
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

7.  A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A.

Authors:  B Voller; T Sycha; B Gustorff; L Schmetterer; S Lehr; H G Eichler; E Auff; P Schnider
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

8.  Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection.

Authors:  T J Coderre; A L Vaccarino; R Melzack
Journal:  Brain Res       Date:  1990-12-03       Impact factor: 3.252

9.  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.

Authors:  Minglei Cui; Sid Khanijou; John Rubino; Kei Roger Aoki
Journal:  Pain       Date:  2004-01       Impact factor: 6.961

10.  Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain.

Authors:  John A Chaddock; John R Purkiss; Frances C G Alexander; Sarah Doward; Sarah J Fooks; Lorna M Friis; Yper H J Hall; Elizabeth R Kirby; Nicola Leeds; Hilary J Moulsdale; Anthony Dickenson; G Mark Green; Wahida Rahman; Rie Suzuki; Michael J Duggan; Conrad P Quinn; Clifford C Shone; Keith A Foster
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.